Phospho-ZC3HC1 (S354) Antibody

What is ZC3HC1 and why is its phosphorylation at S354 important?

ZC3HC1 (Zinc finger C3HC-type protein 1), also known as NIPA (Nuclear-Interacting Partner of ALK), is a multifunctional protein involved in cell cycle regulation and nuclear pore complex function. The protein is an F-box-containing component of the SCF-type E3 ligase (SCFNIPA) complex that controls the completion of S-phase and mitotic entry. Phosphorylation at Serine 354 occurs in late G2 phase and mitosis, inactivating the complex and allowing accumulation of cyclin B1, which is essential for cell cycle progression . Recent research has also identified ZC3HC1 as an inherent component of the nuclear basket (NB), where it interacts with TPR (translocated promoter region) protein to maintain nuclear envelope structure .

What experimental applications are suitable for Phospho-ZC3HC1 (S354) antibodies?

Phospho-ZC3HC1 (S354) antibodies have been validated for multiple experimental applications:

These applications allow researchers to study phosphorylation-dependent localization and function of ZC3HC1 in various cell cycle phases and cell types .

How should I design experiments to study ZC3HC1 phosphorylation during cell cycle progression?

When studying ZC3HC1 phosphorylation during cell cycle:

• Use cell synchronization techniques to obtain populations at specific cell cycle phases:

  • Double thymidine block for G1/S boundary

  • Nocodazole treatment for M-phase

  • Serum starvation for G0/G1

• Confirm cell cycle stage using flow cytometry or parallel immunostaining for phase-specific markers

• Compare phospho-ZC3HC1 (S354) levels between different phases using Western blot (1:500 dilution) with appropriate loading controls

• For tracking dynamic changes, consider time-course experiments after release from synchronization

• Include subcellular fractionation to distinguish nuclear envelope-associated versus soluble ZC3HC1 pools, as studies have shown distribution differences

What are the recommended protocols for immunofluorescence staining with Phospho-ZC3HC1 (S354) antibodies?

Based on published research methodologies:

• Seed cells on appropriate chamber slides (e.g., μ-slide chamber slides)

• Culture cells in medium containing growth factors if studying cell cycle (e.g., 100 ng/mL PDGF-BB)

• Fix cells with cold methanol-acetone solution (preferred over PFA for nuclear proteins)

• Permeabilize with 0.2% Triton-X in 1% BSA/PBS

• Block unspecific binding with 3.5% BSA

• Incubate with primary anti-Phospho-ZC3HC1 (S354) antibody at 1:200 dilution overnight at 4°C

• For co-localization studies, consider co-staining with anti-cyclin B1 (1:200) or anti-tubulin (1:1000)

• Use DAPI for nuclear counterstaining and appropriate fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor 568/488)

• Image using confocal microscopy for optimal resolution of nuclear structures

How can I verify the specificity of Phospho-ZC3HC1 (S354) antibody results?

To ensure specificity of phospho-specific antibody detection:

• Include appropriate controls:

  • Dephosphorylation control: Treat lysate samples with lambda phosphatase prior to immunoblotting

  • Specificity control: Use non-phosphorylated peptide competition

  • Knockdown control: Compare with ZC3HC1 siRNA-treated samples

• Validate using multiple detection methods:

  • Compare results from different techniques (WB, IF, ELISA)

  • Cross-validate with an alternative phospho-ZC3HC1 antibody from a different supplier or clone

• Functional validation:

  • Correlate phosphorylation status with known cell cycle phases

  • Compare signals between proliferating and quiescent cells

How should I interpret contradictory results between Phospho-ZC3HC1 (S354) antibody detection and functional ZC3HC1 assays?

Conflicting data between phosphorylation status and functional outcomes requires systematic troubleshooting:

• Consider biphasic effects: Research has revealed that ZC3HC1 has a biphasic role in proliferation - lower levels promote SMC proliferation while complete loss abrogates proliferation

• Examine temporal dynamics: Phosphorylation at S354 may have different effects depending on cell cycle phase or cellular context

• Investigate compensatory mechanisms: Other phosphorylation sites (e.g., tyrosine residues mentioned in post-translational modifications data) may influence function

• Account for genetic variants: The rs11556924-T allele is associated with lower ZC3HC1 expression and altered cellular phenotypes, which may affect antibody-based results

• Consider cell type-specific mechanisms: ZC3HC1 functions differently in proliferating versus terminally differentiated cells

How can I use Phospho-ZC3HC1 (S354) antibodies to investigate the relationship between ZC3HC1 and vascular disease?

For cardiovascular disease research involving ZC3HC1:

• GWAS follow-up studies:

  • The rs11556924-T variant is associated with reduced risk of coronary artery disease and hypertension

  • Design genotype-phenotype correlation studies using the antibody to assess phosphorylation differences

• Smooth muscle cell experiments:

  • Use the antibody in migration assays (e.g., wound healing or xCELLigence) to correlate phosphorylation with migration rates

  • Compare phosphorylation levels between SMCs of different rs11556924 genotypes

• Neointima formation models:

  • Apply the antibody in arterial injury models to track ZC3HC1 phosphorylation during vascular remodeling

  • Correlate phosphorylation patterns with cyclin B1 accumulation and proliferation markers

• Therapeutic target assessment:

  • Use the antibody to monitor phosphorylation changes in response to potential therapeutic agents targeting the ZC3HC1 pathway

What approaches can I use to study the dual roles of ZC3HC1 in the nuclear basket and cell cycle regulation?

To investigate this dual functionality:

• Co-localization studies:

  • Perform triple immunofluorescence with Phospho-ZC3HC1 (S354), nuclear pore markers, and cell cycle markers

  • Use super-resolution microscopy (e.g., STORM, STED) for precise localization

• Temporal dynamics analysis:

  • Conduct time-lapse imaging with fluorescently tagged ZC3HC1 and phospho-specific antibodies

  • Track changes in localization during cell cycle progression

• Proximity ligation assays:

  • Use in situ PLA to detect interactions between phosphorylated ZC3HC1 and binding partners (e.g., TPR, cyclin B1)

  • Compare interaction profiles between interphase and mitosis

• Domain-specific mutant analysis:

  • Generate phospho-mimetic (S354D) and phospho-resistant (S354A) mutants

  • Use the antibody to validate mutant effects and track mislocalization

What are common technical issues with Phospho-ZC3HC1 (S354) antibody experiments and how can they be resolved?

Common challenges and solutions:

How should samples be prepared to maximize detection of phosphorylated ZC3HC1?

Optimal sample preparation guidelines:

• Cell lysis:

  • Use buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate

  • Add phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4, 1 mM β-glycerophosphate)

  • Include protease inhibitor cocktail

• Subcellular fractionation:

  • For nuclear envelope enrichment, consider detergent-based protocols that preserve nuclear basket integrity

  • Separately analyze soluble and insoluble fractions for comprehensive profiling

• Protein quantification and loading:

  • Standardize protein amounts (15-40 μg recommended for Western blot)

  • Include phosphorylation-insensitive ZC3HC1 antibody in parallel samples for normalization

• Storage considerations:

  • Process samples immediately when possible

  • If storage is necessary, snap-freeze in liquid nitrogen and store at -80°C

  • Avoid repeated freeze-thaw cycles

How can Phospho-ZC3HC1 (S354) antibody studies be integrated with transcriptomics and proteomics approaches?

Integrative research strategies:

• Multi-omic experimental design:

  • Perform parallel phospho-ZC3HC1 antibody detection, RNA-seq, and proteomics on matched samples

  • Use ZC3HC1 knockdown with siRNA as shown in studies (5 nM concentration effective) to generate comparative datasets

• Data integration approaches:

  • Correlate phosphorylation status with differential expression of known ZC3HC1-regulated genes (e.g., SMC markers like LMOD1, TPM1, CNN1, CALD1, ACTA2, and TAGLN)

  • Map protein-protein interactions using phosphorylation-dependent interactome analysis

• Pathway analysis:

  • Integrate phospho-ZC3HC1 detection with expression data for cell division and cytoskeleton organization pathways

  • Analyze datasets using tools like Enrichr for pathway enrichment based on phosphorylation status

What emerging research questions about ZC3HC1 phosphorylation remain to be addressed?

Critical knowledge gaps and future research directions:

• Phosphorylation kinetics:

  • What is the precise temporal dynamics of S354 phosphorylation during cell cycle progression?

  • Which kinases and phosphatases regulate S354 phosphorylation?

• Structural biology:

  • How does S354 phosphorylation alter ZC3HC1 protein conformation and interaction capabilities?

  • Does phosphorylation affect the zinc finger domain functionality?

• Cell type-specific functions:

  • How does ZC3HC1 phosphorylation differ between proliferating and terminally differentiated cells?

  • Are there tissue-specific phosphorylation patterns relevant to disease states?

• Therapeutic potential:

  • Can targeted modulation of ZC3HC1 phosphorylation serve as an intervention for vascular diseases?

  • How does ZC3HC1 phosphorylation status correlate with response to current cardiovascular treatments?

Beyond antibody-based detection, what alternative methods exist for studying ZC3HC1 phosphorylation?

Complementary methodological approaches:

• Mass spectrometry-based phosphoproteomics:

  • Targeted MS/MS analysis focusing on the S354-containing peptide

  • SILAC-based quantitative proteomics to measure phosphorylation stoichiometry

• Genetic approaches:

  • CRISPR-Cas9 to generate endogenous phospho-mimetic or phospho-resistant mutations

  • Site-specific incorporation of phosphoserine using expanded genetic code technologies

• Biosensors and live-cell imaging:

  • Design FRET-based biosensors for real-time tracking of ZC3HC1 phosphorylation

  • Develop phospho-specific nanobodies for live-cell applications

• Computational modeling:

  • Molecular dynamics simulations to predict phosphorylation effects on protein structure

  • Systems biology approaches to model cell cycle-dependent phosphorylation networks

How should researchers design experiments to investigate the biphasic role of ZC3HC1 in cell proliferation?

Strategic experimental design recommendations:

• Dose-response studies:

  • Use graduated siRNA concentrations to achieve partial versus complete knockdown

  • Compare phosphorylation levels across the dosage spectrum

• Temporal analysis:

  • Monitor proliferation at multiple time points (24h, 48h, 72h) as shown in research where effects were observed at 72h but not 24h

  • Track phosphorylation dynamics in parallel with BrdU incorporation

• Genetic complementation:

  • Rescue experiments with wild-type versus phospho-mutant ZC3HC1 in knockout backgrounds

  • Express precise levels of ZC3HC1 using inducible systems

• Single-cell approaches:

  • Correlate phospho-ZC3HC1 levels with cell cycle markers at single-cell resolution

  • Use live-cell tracking to follow individual cells through multiple divisions

• Pathway intervention:

  • Target upstream regulators of ZC3HC1 phosphorylation

  • Modulate related pathway components (e.g., cyclin B1) to assess interdependence